

## Special Issue

# Cancer Immunotherapy and the PD-1/PD-L1 Checkpoint Pathway

### Message from the Guest Editors

In recent years, cancer immunotherapy has made great strides, and, thanks to the understanding of the mechanisms underlying immunity in cancer, numerous therapies have been developed for different tumors. The efficiency of an immune checkpoint blockade with monoclonal antibodies in cancer treatment is remarkable, and an example of this is the success of PD-1/PD-L1 inhibition blockade. The current challenge is to understand the mechanisms of resistance as well as identify new predictive–prognostic markers implicated in the PD-1/PD-L1 checkpoint pathway. The purpose of this Special Issue is to investigate the molecular mechanisms that regulate immunotherapy in terms of response and resistance in depth and to identify biological markers useful for the personalization of therapies.

---

### Guest Editors

Dr. Simona Serrati

IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy

Dr. Francesca Margheri

Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, 50134 Firenze, Italy

---

### Deadline for manuscript submissions

closed (31 May 2025)



## Biomolecules

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.8**  
**CiteScore 9.2**  
**Indexed in PubMed**



[mdpi.com/si/168522](https://mdpi.com/si/168522)

*Biomolecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomolecules@mdpi.com](mailto:biomolecules@mdpi.com)

[mdpi.com/journal/  
biomolecules](https://mdpi.com/journal/biomolecules)





# Biomolecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.2  
Indexed in PubMed



[mdpi.com/journal/  
biomolecules](https://mdpi.com/journal/biomolecules)



## About the Journal

### Message from the Editorial Board

*Biomolecules* is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

---

### Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3C, DK-2200 Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA

---

### Author Benefits

#### Open Access

— free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)